{
    "clinical_study": {
        "@rank": "129273", 
        "arm_group": {
            "arm_group_label": "Gemzar/Abraxane and Radiation Therapy", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given."
        }, 
        "brief_summary": {
            "textblock": "This study will analyze the effects, good and/or bad, of the drug Abraxane in combination\n      with gemcitabine and gemcitabine with concurrent radiation therapy for patients with locally\n      advanced pancreatic cancer that cannot be removed by surgery.  All of the medications used\n      in this study are FDA-approved for use in patients with pancreatic cancer."
        }, 
        "brief_title": "Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer", 
        "completion_date": {
            "#text": "March 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The long term goal is to improve survival of patients with unresectable pancreatic cancer.\n      Additional potential benefits include increased probability of local control and decreased\n      distant metastases."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically proven carcinoma of the pancreas that is locally\n             advanced\n\n          -  ECOG performance status 0- 2\n\n          -  Adequate labs\n\n          -  No prior abdominal radiation therapy\n\n          -  No other concurrent clinically evident malignancy, except inactive nonmelanoma skin\n             cancer, inactive cervical cancer, or other cancer for which the patient has been\n             disease-free for 5 years\n\n          -  All disease must be encompassed within a radiotherapy portal\n\n          -  Not pregnant or nursing\n\n        Exclusion Criteria:\n\n          -  Patient has metastatic disease on radiological staging\n\n          -  systemic therapy.\n\n          -  Patient has known active infection with HIV, hepatitis C or hepatitis B\n\n          -  Patient has serious medical risk factors involving any of the major organ systems\n             such that the Investigator considers it unsafe for the patient to receive an\n             experimental research drug.\n\n          -  Patient is deemed to be have obvious resectable disease at presentation\n\n          -  Received any investigational agent within a month prior to enrollment.\n\n          -  Neuroendocrine tumors of the pancreas"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693276", 
            "org_study_id": "UCC-GI-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gemzar/Abraxane and Radiation Therapy", 
                "description": "gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.\nGemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "Gemzar/Abraxane and Radiation Therapy", 
                "description": "Abraxane\u00ae 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT", 
                "intervention_name": "Abraxane", 
                "intervention_type": "Drug", 
                "other_name": "nab-Paclitaxel"
            }, 
            {
                "arm_group_label": "Gemzar/Abraxane and Radiation Therapy", 
                "description": "IMRT Dose escalation: 60 Gy (2 Gy/fraction)", 
                "intervention_name": "Radiation Therapy", 
                "intervention_type": "Radiation", 
                "other_name": "RT"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "pancreatic cancer", 
        "lastchanged_date": "October 23, 2013", 
        "location": {
            "contact": {
                "last_name": "UC Cancer Institute", 
                "phone": "513-584-7698"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45219"
                }, 
                "name": "University of Cincinnati"
            }, 
            "investigator": [
                {
                    "last_name": "Olugbenga Olowokure, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Michelle Mierzwa, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer", 
        "overall_contact": {
            "last_name": "UC Cancer Institute", 
            "phone": "513-584-7698"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Cincinnati", 
                "last_name": "Olugbenga Olowokure, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Cincinnati", 
                "last_name": "Michelle Mierzwa, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Estimated increase in median survival from 11 to 16 months", 
            "measure": "Increase overall survival", 
            "safety_issue": "No", 
            "time_frame": "23 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693276"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Olugbenga Olowokure", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Determine rate of local control from the date of start of treatment to the date of the time of local progression", 
            "measure": "Rate of local control", 
            "safety_issue": "No", 
            "time_frame": "baseline to average up to 24 weeks"
        }, 
        "source": "University of Cincinnati", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Olugbenga Olowokure", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}